Treatment of refractory bleeding after cardiac operations with low-dose recombinant activated factor VII (NovoSeven®): a propensity score analysis

Abstract

In our experience low-dose rFVIIa was associated with reduced blood loss, improvement of coagulation variables and decreased need for transfusions. Our findings need to be confirmed by further larger studies.